BR112016016356A2 - Imunoterapia baseada em lipossomas - Google Patents
Imunoterapia baseada em lipossomasInfo
- Publication number
- BR112016016356A2 BR112016016356A2 BR112016016356A BR112016016356A BR112016016356A2 BR 112016016356 A2 BR112016016356 A2 BR 112016016356A2 BR 112016016356 A BR112016016356 A BR 112016016356A BR 112016016356 A BR112016016356 A BR 112016016356A BR 112016016356 A2 BR112016016356 A2 BR 112016016356A2
- Authority
- BR
- Brazil
- Prior art keywords
- liposome
- pharmaceutical
- veterinary compositions
- based immunotherapy
- defined above
- Prior art date
Links
- 238000009169 immunotherapy Methods 0.000 title abstract 2
- 239000002502 liposome Substances 0.000 abstract 5
- 239000000203 mixture Substances 0.000 abstract 4
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 abstract 2
- 208000023275 Autoimmune disease Diseases 0.000 abstract 2
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 abstract 2
- 239000012528 membrane Substances 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/577—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 tolerising response
Abstract
IMUNOTERAPIA BASEADA EM LIPOSSOMAS. A presente invenção refere-se a um lipossoma que encapsula um autoantígeno, em que o lipossoma tem um tamanho compreendido de 500 a 15000 nm; e a membrana lipossomal compreende fosfatidilserina (FS) em uma quantidade compreendida de 10 a 40% em peso em relação à composição total da membrana lipossomal. Composições farmacêuticas ou veterinárias que compreendem uma quantidade terapeuticamente eficaz do dito lipossoma também são fornecidas. Além disso, a invenção fornece lipossomas e composições farmacêuticas ou veterinárias, conforme definido acima, para uso como um medicamento, particularmente para o tratamento de doenças autoimunes. Finalmente, a presente invenção fornece lipossomas e composições farmacêuticas ou veterinárias, conforme definidos acima, para uso na restauração da autotolerância em um paciente que sofre de uma doença autoimune.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14151629 | 2014-01-17 | ||
| EP14151629.4 | 2014-01-17 | ||
| PCT/EP2015/050747 WO2015107140A1 (en) | 2014-01-17 | 2015-01-16 | Liposome-based immunotherapy |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| BR112016016356A2 true BR112016016356A2 (pt) | 2017-10-03 |
| BR112016016356B1 BR112016016356B1 (pt) | 2023-12-26 |
Family
ID=49949574
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112016016356-7A BR112016016356B1 (pt) | 2014-01-17 | 2015-01-16 | Lipossoma, usos dos mesmos, e composição farmacêutica ou veterinária |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20160338953A1 (pt) |
| EP (1) | EP3094345B1 (pt) |
| JP (2) | JP6546195B2 (pt) |
| CN (1) | CN106061502B (pt) |
| AU (1) | AU2015206016B2 (pt) |
| BR (1) | BR112016016356B1 (pt) |
| CA (1) | CA2939435C (pt) |
| ES (1) | ES2672247T3 (pt) |
| MX (1) | MX2016009217A (pt) |
| PL (1) | PL3094345T3 (pt) |
| TR (1) | TR201807778T4 (pt) |
| WO (1) | WO2015107140A1 (pt) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL3094345T3 (pl) * | 2014-01-17 | 2018-11-30 | Fundació Institut D'investigació En Ciències De La Salut Germans Trias I Pujol | Immunoterapia oparta na liposomach |
| EP2918262B1 (en) * | 2014-03-10 | 2023-08-09 | PLS-Design GmbH | Induction of antigen-specific tolerance by peripheral phagocytosis |
| AU2017394032B8 (en) | 2017-01-21 | 2020-10-22 | Guangzhou Hanfang Pharmaceutical Co., Ltd. | Use of paeoniflorin-6'-o-benzenesulfonate in treatment of sjögren's syndrome |
| WO2018156875A1 (en) * | 2017-02-24 | 2018-08-30 | Ebner Todd Rene | Nutrition management and kitchen appliance |
| US20220409702A1 (en) * | 2019-11-22 | 2022-12-29 | The Research Foundation For The State University Of New York | Compositions and methods for use in type 1 diabetes |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5542935A (en) * | 1989-12-22 | 1996-08-06 | Imarx Pharmaceutical Corp. | Therapeutic delivery systems related applications |
| ES2305157T3 (es) * | 1996-09-13 | 2008-11-01 | Lipoxen Technologies Limited | Liposomas. |
| CA2319928A1 (en) * | 2000-09-18 | 2002-03-18 | Vasogen Ireland Limited | Apoptosis-mimicking synthetic entities and use thereof in medical treatments |
| EP1547581A1 (en) * | 2003-12-23 | 2005-06-29 | Vectron Therapeutics AG | Liposomal vaccine for the treatment of human hematological malignancies |
| EP1767216B1 (en) * | 2004-06-11 | 2012-07-11 | Riken | Drug having regulatory cell ligand contained in liposome |
| CN101588813A (zh) * | 2005-04-12 | 2009-11-25 | 杜克大学 | 诱导人类免疫缺陷病毒的中和抗体的方法 |
| EP1909758A1 (en) * | 2005-08-02 | 2008-04-16 | I.D.M. Immuno-Designed Molecules | Process for the preparation of liposomal formulations |
| US10736848B2 (en) * | 2007-10-12 | 2020-08-11 | Massachusetts Institute Of Technology | Vaccine nanotechnology |
| WO2009101207A1 (en) * | 2008-02-14 | 2009-08-20 | Life Sciences Research Partners Vzw | Cd4+ t-cells with cytolytic properties |
| CN101502649B (zh) * | 2008-06-23 | 2011-11-30 | 深圳职业技术学院 | 一种脂质体流感疫苗 |
| WO2011005850A1 (en) * | 2009-07-07 | 2011-01-13 | The Research Foundation Of State University Of New York | Lipidic compositions for induction of immune tolerance |
| EP2672958A1 (en) * | 2011-02-08 | 2013-12-18 | Halozyme, Inc. | Composition and lipid formulation of a hyaluronan-degrading enzyme and the use thereof for treatment of benign prostatic hyperplasia |
| WO2012149393A2 (en) * | 2011-04-29 | 2012-11-01 | Selecta Biosciences, Inc. | Tolerogenic synthetic nanocarriers for antigen-specific deletion of t effector cells |
| WO2013184976A2 (en) * | 2012-06-06 | 2013-12-12 | Northwestern University | Compositions and methods for antigen-specific tolerance |
| PL3094345T3 (pl) * | 2014-01-17 | 2018-11-30 | Fundació Institut D'investigació En Ciències De La Salut Germans Trias I Pujol | Immunoterapia oparta na liposomach |
-
2015
- 2015-01-16 PL PL15700478T patent/PL3094345T3/pl unknown
- 2015-01-16 US US15/111,466 patent/US20160338953A1/en active Pending
- 2015-01-16 AU AU2015206016A patent/AU2015206016B2/en active Active
- 2015-01-16 MX MX2016009217A patent/MX2016009217A/es active IP Right Grant
- 2015-01-16 CN CN201580007978.3A patent/CN106061502B/zh active Active
- 2015-01-16 TR TR2018/07778T patent/TR201807778T4/tr unknown
- 2015-01-16 ES ES15700478.9T patent/ES2672247T3/es active Active
- 2015-01-16 CA CA2939435A patent/CA2939435C/en active Active
- 2015-01-16 EP EP15700478.9A patent/EP3094345B1/en active Active
- 2015-01-16 BR BR112016016356-7A patent/BR112016016356B1/pt active IP Right Grant
- 2015-01-16 WO PCT/EP2015/050747 patent/WO2015107140A1/en active Application Filing
- 2015-01-16 JP JP2016564400A patent/JP6546195B2/ja active Active
-
2019
- 2019-06-20 JP JP2019114294A patent/JP2019196363A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP3094345B1 (en) | 2018-03-14 |
| CN106061502B (zh) | 2021-04-13 |
| TR201807778T4 (tr) | 2018-06-21 |
| JP6546195B2 (ja) | 2019-07-17 |
| AU2015206016B2 (en) | 2020-07-23 |
| EP3094345A1 (en) | 2016-11-23 |
| CN106061502A (zh) | 2016-10-26 |
| US20160338953A1 (en) | 2016-11-24 |
| JP2019196363A (ja) | 2019-11-14 |
| WO2015107140A1 (en) | 2015-07-23 |
| CA2939435C (en) | 2023-09-19 |
| CA2939435A1 (en) | 2015-07-23 |
| AU2015206016A1 (en) | 2016-08-25 |
| ES2672247T3 (es) | 2018-06-13 |
| JP2017507171A (ja) | 2017-03-16 |
| MX2016009217A (es) | 2017-05-12 |
| BR112016016356B1 (pt) | 2023-12-26 |
| PL3094345T3 (pl) | 2018-11-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112018003898A2 (pt) | material auxiliar para aplicação no tecido de cólon | |
| BR112016016356A2 (pt) | Imunoterapia baseada em lipossomas | |
| BR112013031268A2 (pt) | "polipeptídeos análogos de pramlintida, uso dos mesmos, composição farmacêutica compreendendo os referidos polipeptídeos e método de preparação da referida composição". | |
| BR112015014372A8 (pt) | inibidores de autotaxina, seus usos, e composição e combinação farmacêuticas". | |
| BR112015022096A8 (pt) | compostos moduladores de canal de sódio, composição que os compreende e uso dos mesmos | |
| BR112015001955A2 (pt) | variante de região fc específica de fcgamariib | |
| BR112012016853A2 (pt) | "composições farmacêuticas para administração oral de peptídeos de insulina". | |
| CL2012001605A1 (es) | Compuestos derivados de quinolina-2-carboxamida, moduladores alostericos positivos del receptor muscarino m1; composicion farmaceutica que comprende al compuesto; y su uso en la preparacion de medicamentos para el tratamiento de enfermedades tales como alzheimer, trastornos del dolor o del sueño. | |
| DOP2015000005A (es) | Derivados de estra 1,3,5(10), 16 tetraeno 3 sustituidos, métodos para su preparación, preparaciones farmacéuticas que los contienen, así como su uso para la preparación de medicamentos | |
| EA201500365A1 (ru) | Комбинация регорафениба и ацетилсалициловой кислоты для лечения рака | |
| BR112015010779A2 (pt) | moduladores de di-hidropirazol gpr40 | |
| BR112015010791A2 (pt) | moduladores de gpr40 de di-hidropirazol | |
| ECSP14013275A (es) | Derivados de estra-1,3,5(10),16-tetraen-3-carboxamida, procedimientos para su preparación, preparados farmacéuticos que los contienen, así como su uso para la preparación de medicamentos | |
| BR112012022552A8 (pt) | uso de fenoterol e de análogos de fenoterol no tratamento de gliobastomas e astrocitomas e composição farmacêutica compreendendo os referidos compostos | |
| CL2012001836A1 (es) | Compuestos de pirazol, antagonista de crth2; composicion farmacéutica; uso en el tratamiento de trastornos inflamatorios, infecciosos, inmunoreguladores, enfermedades respiratorias, gastrointestinales o dolencias, entre otros. | |
| BR112014018953A8 (pt) | Derivados de lupano triterpenoide e uso farmacêutico dos mesmos | |
| BR112016030774A2 (pt) | anticorpo ou fragmento de ligação a antígeno do mesmo, uso de um anticorpo, métodos para redução da quantidade de protofibrilas de ?? em um indivíduo, para tratamento e/ou para profilaxia de uma doença, para medição da quantidade de protofibrilas de ?? e/ou de proteína ?? agregada em uma pessoa, e para diagnóstico de uma doença, e, composição farmacêutica | |
| UY35276A (es) | Nuevos compuestos que inhiben la actividad de Lp-PLA2 | |
| BR112014005025A2 (pt) | composição farmacêutica para uso no tratamento de uma doença neurodegenerativa | |
| BR112015022650A2 (pt) | inibidores de cinase induzível por sal macrocíclico | |
| BR112015022415A2 (pt) | composições de cisplatina lipossômica para terapia contra câncer | |
| BR112015001521A2 (pt) | previsão de resposta ao tratamento para inibidor jak/stat | |
| DOP2013000314A (es) | Composición farmacéutica oftalmológica tópica que contiene regorafenib | |
| GT201300125A (es) | 1h-pirazol-5-olato sódico sustituido | |
| MX367926B (es) | Composicion farmaceutica para liberacion sostenida de lanreotida. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 16/01/2015, OBSERVADAS AS CONDICOES LEGAIS |